Vivos Therapeutics announced a partnership with SoundHealth to distribute the company’s Sonu Band and Spatial Sleep devices through its national network of more than 2,000 dentists and sleep‑care providers. The Sonu Band is FDA‑cleared for treating nasal congestion and improving CPAP compliance, while the Spatial Sleep band uses acoustic resonance to deepen sleep.
The collaboration gives Vivos access to SoundHealth’s AI‑driven facial‑scanning and voice‑biomarker technology, which can enhance screening and monitoring in Vivos’ sleep‑testing centers. By adding these airway‑health products to its existing oral‑appliance line, Vivos broadens its treatment options for obstructive sleep apnea and related breathing disorders.
Vivos CEO Kirk Huntsman said the partnership “leverages SoundHealth’s advanced technology to strengthen Vivos’ position as a comprehensive, non‑invasive airway solution provider.” SoundHealth CEO Paramesh Gopi added that the deal aligns with Vivos’ mission to deliver practical, drug‑free breathing and sleep solutions.
The partnership is expected to increase patient volume and revenue streams for Vivos by tapping into its established provider network. Vivos reported a 76% year‑over‑year revenue rise to $6.8 million in Q3 2025, although losses widened and the company recently raised $4.64 million through warrant exercises. The deal positions Vivos to capture a larger share of the $30 billion global sleep‑technology market, which is shifting toward active airway interventions.
Investors reacted positively to the announcement, reflecting confidence in Vivos’ expanded product portfolio and the potential for higher margins from a broader direct‑care model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.